Skip to main
NBTX

Nanobiotix SA (NBTX) Stock Forecast & Price Target

Nanobiotix SA (NBTX) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Nanobiotix is in the later stage of clinical development, and analysts are optimistic about its potential to transform cancer treatment using its novel physics-based approach. With a promising lead product and partnerships with reputable companies such as JNJ, Nanobiotix has the potential for significant revenue streams through milestones and royalties. Risks include clinical and regulatory setbacks, commercial challenges, and potential funding needs before achieving positive cash flow. However, the recent royalty monetization agreement with HCRx and positive updates on trials have increased analyst confidence, leading to a PT revision to $36 per ADR from $26 previously.

Bears say

Nanobiotix is highly dependent on the success and approval of their lead product, NBTXR3, with a 50% probability of success in the LA HNSCC market and a 45% probability of success in the R/M HNSCC market, which poses significant risks to the company's growth and financial stability. In addition, their revenue projections heavily rely on milestone payments and royalty revenue, which could be impacted by any delays or failures in clinical trials. The company also faces risks such as potential legal issues and government intervention in drug pricing, which could impact their financial results.

Nanobiotix SA (NBTX) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nanobiotix SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nanobiotix SA (NBTX) Forecast

Analysts have given Nanobiotix SA (NBTX) a Buy based on their latest research and market trends.

According to 3 analysts, Nanobiotix SA (NBTX) has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nanobiotix SA (NBTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.